Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting
06 November 2023 - 1:00PM
Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage
biopharmaceutical company focused on developing tumor infiltrating
lymphocyte, or TIL, therapies for the treatment of patients with
cancer, today reported two poster presentations at the SITC 2023
Annual Meeting demonstrating that its proprietary CoStimulatory
Antigen Receptor (CoStAR™) platform enhances the activity of CD4+ T
cells across multiple axes.
TIL therapy utilizes a mixed population of tumor-reactive CD4+
and CD8+ T cells, with both populations of T cells able to drive
tumor regression. CoStAR has previously been demonstrated to
improve proliferation, secretion of soluble factors, and in vivo
tumor control in preclinical studies with mixed populations of CD4+
and CD8+ T cells. New single-cell RNA sequencing data presented at
the SITC 2023 Annual Meeting revealed enhanced gene signatures of
activation and cytotoxicity in CoStAR-transduced CD4+ T cells, with
significant increases in cytotoxic function of these CD4+ T cells
in an in vitro cytotoxicity assay. These data suggest that CoStAR
is able to endow CD4+ T cells with novel cell-killing capacity,
potentially broadening the repertoire of tumor-killing TIL to
include CD4+ T cells in addition to naturally cytotoxic CD8+ T
cells.
Additionally, CoStAR was demonstrated to enhance the secretion
of soluble factors from CD4+ T cells to boost the proliferation and
survival of companion CD8+ T cells. As CoStAR provides
proliferative benefit to mixed populations of CD4+ and CD8+ T
cells, these data demonstrate the importance of CD4+ CoStAR-T cells
in supporting the proliferation of CD8+ CoStAR-T cells through the
provision of soluble factors.
“The data presented at the SITC 2023 Annual Meeting reinforce
the potential of CoStAR to broadly enhance the function of TIL
therapies through multiple functional enhancements,” said Bronson
Crouch, CEO of Instil.
Posters may be found on the Instil Bio Publications webpage:
POSTER | SITC ANNUAL MEETING, NOVEMBER 3-5
2023Single cell RNA sequencing reveals functionally
validated signatures of cytotoxicity in anti-FRα CoStimulatory
Antigen Receptor (CoStAR™) activated CD4+ T cells.
POSTER | SITC ANNUAL MEETING, NOVEMBER 3-5
2023Anti-folate receptor alpha (FRα) CoStimulatory Antigen
Receptor (CoStAR™) drives distinct cytokine-mediated proliferation
responses in CD4+ and CD8+ T cells.
About Instil Bio
Instil Bio, Inc. (Nasdaq: TIL) is a clinical-stage
biopharmaceutical company focused on developing TIL therapies for
the treatment of patients with cancer. Instil has assembled an
accomplished management team with a successful track record in the
research, development and manufacture of cell therapies. Using its
proprietary and optimized manufacturing processes at its in-house
manufacturing facility, Instil is developing a novel class of
genetically engineered TIL therapies using its Co-Stimulatory
Antigen Receptor, or CoStAR™, platform, including ITIL-306, a
next-generation, genetically-engineered TIL therapy for multiple
solid tumors. For more information visit www.instilbio.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “anticipates,” “believes,” “expects,” “future,”
“intends,” “plans,” “potential,” “projects,” and “will” or similar
expressions are intended to identify forward-looking statements.
Forward-looking statements include statements concerning or
implying the therapeutic potential of our preclinical data, our
product candidates, our research, development and regulatory plans
for our product candidates, the timing of our ongoing and potential
future clinical trials and studies and the availability and
presentation of data therefrom, including our expectations
concerning the initiation of, and timing of updates on, our
ITIL-306-202 clinical trial, the potential for us to make
submissions concerning, and for our product candidates to receive,
regulatory approval from the FDA, MHRA or equivalent foreign
regulatory agencies and whether, if approved, these product
candidates will be successfully distributed and marketed, our cash
runway, and other statements that are not historical fact.
Forward-looking statements are based on management's current
expectations and are subject to various risks and uncertainties
that could cause actual results to differ materially and adversely
from those expressed or implied by such forward-looking statements,
including risks and uncertainties associated with the costly and
time-consuming cell therapy product development process and the
uncertainty of clinical success, including risks related to failure
or delays in successfully initiating, enrolling, reporting data
from or completing clinical studies, as well as the risks that
results obtained in preclinical studies or clinical trials to date
may not be indicative of results obtained in ongoing or future
trials and that Instil’s product candidates may otherwise not be
effective treatments in their planned indications; macroeconomic
conditions, including as a result of the ongoing COVID-19 pandemic,
the ongoing conflict between Russia and Ukraine and the conflict in
the Middle East, bank failures and other factors, which could
materially and adversely affect Instil’s business and operations,
including Instil's ability to timely initiate, enroll and complete
its ongoing and future clinical trials; the time-consuming and
uncertain regulatory approval process; risks inherent in
manufacturing and testing of cell therapy products; the sufficiency
of Instil’s cash resources, and other risks and uncertainties
affecting Instil and its development programs, including those
discussed in the section titled “Risk Factors” in our Annual Report
on Form 10-K for the year ended December 31, 2022 available on
the SEC’s website at www.sec.gov, and in our Quarterly Report on
Form 10-Q for the quarter ended June 30, 2023 filed with the
SEC. Additional information will be made available in other filings
that we make from time to time with the SEC. Accordingly, these
forward-looking statements do not constitute guarantees of future
performance, and you are cautioned not to place undue reliance on
these forward-looking statements. These forward-looking statements
speak only as the date hereof, and we disclaim any obligation to
update these statements except as may be required by law.
Contacts:
Investor
Relations1-972-499-3350investorrelations@instilbio.comwww.instilbio.com
Instill Bio (NASDAQ:TIL)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Instill Bio (NASDAQ:TIL)
Historical Stock Chart
Von Mai 2023 bis Mai 2024